Literature DB >> 24011867

Targeting cyclin-dependent kinases in anti-neoplastic therapy.

Céline Bruyère1, Laurent Meijer.   

Abstract

Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24011867     DOI： 10.1016/j.ceb.2013.08.004

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN： 0955-0674            Impact factor:   8.382


  29 in total

Review 1.  Targeting cancer with kinase inhibitors.

Authors:  Stefan Gross; Rami Rahal; Nicolas Stransky; Christoph Lengauer; Klaus P Hoeflich
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

Review 2.  CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Authors:  Belinda Lee; Grant A McArthur
Journal:  Melanoma Manag       Date:  2015-08-10

3.  PARK2 orchestrates cyclins to avoid cancer.

Authors:  Jiri Bartek; Zdenek Hodny
Journal:  Nat Genet       Date:  2014-06       Impact factor: 38.330

Review 4.  Roscovitine in cancer and other diseases.

Authors:  Jonas Cicenas; Karthik Kalyan; Aleksandras Sorokinas; Edvinas Stankunas; Josh Levy; Ingrida Meskinyte; Vaidotas Stankevicius; Algirdas Kaupinis; Mindaugas Valius
Journal:  Ann Transl Med       Date:  2015-06

5.  PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.

Authors:  Octavian Bucur; Andreea Lucia Stancu; Maria Sinziana Muraru; Armelle Melet; Stefana Maria Petrescu; Roya Khosravi-Far
Journal:  Discoveries (Craiova)       Date:  2014 Apr-Jun

6.  Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.

Authors:  Nicolas Floquet; Mauricio G S Costa; Paulo R Batista; Pedro Renault; Paulo M Bisch; Florent Raussin; Jean Martinez; May C Morris; David Perahia
Journal:  Biophys J       Date:  2015-08-06       Impact factor: 4.033

7.  Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma.

Authors:  Renan Chang; Lixian Wei; Yuhua Lu; Xiaopeng Cui; Cuihua Lu; Luoliang Liu; Dawei Jiang; YiCheng Xiong; Gang Wang; Chunhua Wan; Haixin Qian
Journal:  J Mol Histol       Date:  2014-10-14       Impact factor: 2.611

8.  Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.

Authors:  Xianzhe Liu; Yan Gao; Jacson Shen; Wen Yang; Edwin Choy; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Mol Cancer Ther       Date:  2016-05-20       Impact factor: 6.261

Review 9.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

Review 10.  Targeting cell cycle regulators in hematologic malignancies.

Authors:  Eiman Aleem; Robert J Arceci
Journal:  Front Cell Dev Biol       Date:  2015-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.